基线肿瘤浸润淋巴细胞模式与转移性皮肤黑色素瘤免疫检查点抑制剂疗效的关联
这项多中心队列研究纳入接受一线抗PD1±抗CTLA4治疗的晚期黑色素瘤患者,用三种评分方法在苏木精-伊红(H&E)切片上评估原发灶与转移灶的肿瘤浸润淋巴细胞(TILs)。转移灶TILs-WG评分每增加10分与客观缓解率更高、无进展生存期和总生存期改善独立相关;原发灶标本未见关联。
要点
- 转移灶TILs-WG评分每增加10分与缓解概率更高相关(aOR 1.17,95%CI 1.07-1.28)。
- 转移灶TILs-WG最高三分位(15-100%)较低三分位(0%)中位无进展生存期更长(13.1 vs 7.3个月,p=0.04)。
- 转移灶TILs-WG最高三分位(15-100%)较低三分位(0%)中位总生存期更长(49.4 vs 19.5个月,p=0.003)。
核心结论
- 在晚期黑色素瘤患者中,治疗前转移灶H&E切片上的TIL模式无论采用哪种测量方法,均与免疫检查点抑制剂疗效独立相关。
- TILs在易获取的H&E切片上易于评分,有助于该生物标志物在临床实践中的应用。
研究设计与样本
- 多中心队列研究,纳入接受一线抗PD1±抗CTLA4治疗的晚期黑色素瘤患者。
- 转移灶标本可获取650例,原发灶标本可获取565例。
- 采用经验证的TILs-WG、Clark和MIA评分在苏木精-伊红(H&E)切片上评估原发灶与治疗前转移灶的TILs。
- 主要结局为客观缓解率(ORR),无进展生存期和总生存期为次要结局。
- 采用单因素和多因素logistic回归及Cox比例风险模型,并校正已知临床预测因素。
主要发现
- 原发灶标本中未发现TILs与疗效的关联。
- 转移灶TILs-WG评分每增加10分与缓解概率更高相关(aOR 1.17,95%CI 1.07-1.28)。
- 转移灶TILs-WG评分每增加10分与无进展生存期改善相关(HR 0.93,95%CI 0.87-0.996)。
- 转移灶TILs-WG评分每增加10分与总生存期改善相关(HR 0.94,95%CI 0.89-0.99)。
- 转移灶TILs-WG最高三分位(15-100%)较低三分位(0%)中位无进展生存期更长(13.1 vs 7.3个月,p=0.04)、中位总生存期更长(49.4 vs 19.5个月,p=0.003)。
关键数值与推荐
- 转移灶TILs-WG评分每增加10分:aOR 1.17(95%CI 1.07-1.28)。
- 转移灶TILs-WG评分每增加10分:无进展生存期HR 0.93(95%CI 0.87-0.996)。
- 转移灶TILs-WG评分每增加10分:总生存期HR 0.94(95%CI 0.89-0.99)。
- 转移灶TILs-WG最高三分位(15-100%)vs 最低三分位(0%):中位无进展生存期13.1 vs 7.3个月(p=0.04)。
- 转移灶TILs-WG最高三分位(15-100%)vs 最低三分位(0%):中位总生存期49.4 vs 19.5个月(p=0.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The presence of tumor-infiltrating lymphocytes (TILs) in melanoma has been linked to survival. Their predictive capability for immune checkpoint inhibition (ICI) response remains uncertain. Therefore, we investigated the association between treatment response and TILs in the largest cohort to date and analyzed if this association was independent of known clinical predictors. METHODS: In this multicenter cohort study, patients who received first-line anti-PD1 ± anti-CTLA4 for advanced melanoma were identified. TILs were scored on hematoxylin and eosin (H&E) slides of primary melanoma and pre-treatment metastases using the validated TILs-WG, Clark and MIA score. The primary outcome was objective response rate (ORR), with progression free survival and overall survival being secondary outcomes. Univariable and multivariable logistic regression and Cox proportional hazard were performed, adjusting for known clinical predictors. RESULTS: Metastatic melanoma specimens were available for 650 patients and primary specimens for 565 patients. No association was found in primary melanoma specimens. In metastatic specimens, a 10-point increase in the TILs-WG score was associated with a higher probability of response (aOR 1.17, 95 % CI 1.07-1.28), increased PFS (HR 0.93, 95 % CI 0.87-0.996), and OS (HR 0.94, 95 % CI 0.89-0.99). When categorized, patients in the highest tertile TILs-WG score (15-100 %) compared to the lowest tertile (0 %) had a longer median PFS (13.1 vs. 7.3 months, p = 0.04) and OS (49.4 vs. 19.5 months, p = 0.003). Similar results were noted using the MIA and Clark scores. CONCLUSION: In advanced melanoma patients, TIL patterns on H&E slides of pre-treatment metastases, regardless of measurement method, are independently associated with ICI response. TILs are easily scored on readily available H&Es, facilitating the use of this biomarker in clinical practice.
引用
- van Duin IAJ, Schuiveling M, Ter Maat LS, et al. Baseline tumor-infiltrating lymphocyte patterns and response to immune checkpoint inhibition in metastatic cutaneous melanoma. Eur J Cancer. 2024. PMID: 38991284. doi:10.1016/j.ejca.2024.114190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。